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While Cochrane reviews, as rigorous evaluations of evidence in health care, have substantial 
impact on clinical and policy decision-making, it is important to contextualize their findings as 
well as methods. These reviews are conducted by groups of academics who may or may not 
have adequate expertise or clinical experience in the field they examine and the methods are 
prescribed and conservative.  
 
The recent Cochrane review of intervention trials for patients at high risk of psychosis1 
concludes that despite the considerable research effort in this area, the evidence base is weak 
and no firm conclusions can yet be drawn. They note that the ‘strongest weak evidence’ is for 
omega-3 fatty acids in preventing onset of psychosis in this population, but that the quality of 
evidence overall is low to very low.  
 
We have several methodological concerns about the review. Firstly, a significant contributor 
to the low to very low-quality rating of studies is their risk of bias (e.g., randomisation and 
allocation concealment methods not being described, unblinding risk, and high attrition). 
However, most studies included are psychosocial/psychotherapy trials, where it is impossible 
to blind therapists and notoriously difficult to maintain patient blinding and high rates of 
attrition are common in all trials of youth with mental disorders. Moreover, many studies 
employed rigorous methods of randomisation and allocation concealment without detailing 
these in print.  
 
Secondly, the 50% reduction in symptoms used to judge clinical improvement, derived from 
studies of medications for acutely unwell patients with psychosis2, may be inappropriate as a 
criterion for this clinical group, setting the bar too high for a patient group who by definition 
have symptoms of moderate intensity. Indeed, even in clinical trials of 
pharmacological/psychological interventions for acutely ill FEP and schizophrenia patients, 
response is usually set between 20-50% symptom reduction.e.g. 3 
 
Thirdly, the review takes the approach of comparing different categories of interventions 
across RCTs with control conditions. While this is arguably a better approach than network 
 3 
meta-analyses, it means that the critical issue of whether specific targeted interventions when 
all pooled together are superior to standard treatment is left unaddressed. When this issue has 
been addressed, as has been done several times now4-6 (although not including all intervention 
trials due to time of publication), it is clear that the onset of psychosis can at least be delayed 
in this clinical population through specific targeted treatments, with a 50% risk reduction over 
12 months. 
 
Other general concerns:  
 
Despite the review demonstrating the benefits of CBT over supportive therapy with a number 
needed to treat (NNT) of 13 over one-year and a relative risk of 0.45 (~8% vs 16% transition 
rate), the conclusions and summary sections downplay this important finding. A NNT of 13 is 
certainly clinically meaningful and compares favourably with psychosis relapse prevention 
using antipsychotic medication7 and treatments in other areas of medicine.8 The diminution 
over time for the effect of CBT is not unique, with treatments needing to be sustained in many 
health conditions (antipsychotic medication for psychosis relapse prevention, insulin for 
diabetes, etc.).   
 
The review ignores biological analysis from the RCTs that supports the protective function of 
omega-3 fatty acids. These studiese.g. 9 indicate that omega-3 levels at baseline and their 
increase in trial participants predicts clinical improvement, highlighting the potential value of 
omega-3 fatty acids as a treatment option.  
   
The authors correctly point out that treatment studies have consistently been underpowered. 
Although prioritising multisite studies to increase sample size is certainly one solution, the 
review ignores the importance of enriching samples in order to adequately evaluate preventive 
treatments. Stratification of risk within high risk cohorts is a highly active area of research.  
 
Standard treatment is not a fixed entity. It is likely that background service-level contextual 
factors have improved over time and that standard treatment has been refined. This means 
that the control/comparison conditions have likely become more effective in recent trials, 
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which, coupled with the observed rise in placebo response, means that trial interventions need 
to improve on already effective treatments.  
 
Finally, the authors suggest future treatment studies take a two-stage approach that firstly 
compares low-dose, antipsychotic medication versus psychosocial treatment-as-usual before 
progressing to a second step that compares different components of the psychosocial 
treatment-as-usual. The choice to first trial antipsychotic medications is incongruent with the 
evidence base, with an unfavourable risk-benefit ratio. 
 
While it is of course necessary to regularly review the evidence base, details of the 
methodological approach taken and the broader context of treatment trials are essential. 
Although we agree that further high quality research (trials) is needed to enhance outcomes 
and determine the most effective type and sequence of interventions, the evidence base 
shows that help-seeking individuals at high risk for psychosis benefit from the available 
treatments, including ‘standard treatment’, without iatrogenic harm associated with 
antipsychotic medications.10 This potential for improvement is a key message that patients, 
families and practitioners should be made aware of rather than negatively frame the evidence 
base and fail to convey any treatment benefits, which we are concerned is the inaccurate 
message of this recent Cochrane review. If heeded, the review’s message would result in many 
help-seeking young people being denied much needed psychosocial care and exposed to risks 
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